Nonalcoholic fatty liver disease (NAFLD) is a fast growing, chronic liver disease affecting∼
25% of the global population. Nonalcoholic fatty liver disease severity ranges from the less …

Obesity is a global epidemic and overwhelming evidence indicates that it is a risk factor for
numerous cancers, including hepatocellular carcinoma (HCC), the third leading cause of …

Developmental arsenic exposure leads to increased susceptibility to liver diseases including
nonalcoholic fatty liver diseases, but the mechanism is incompletely understood. In this …

Background and aims. Metabolic Associated Fatty Liver Disease (MAFLD) encompasses a
spectrum of diseases from simple steatosis to nonalcoholic steatohepatitis (NASH). Here, we …

Metabolic-associated fatty liver disease (MAFLD) is characterized by hepatic steatosis
accompanied by one of three features: overweight or obesity, T2DM, or lean or normal …

Background: Alcohol-associated liver disease (ALD) is a syndrome of progressive
inflammatory liver injury and vascular remodeling associated with long-term heavy intake of …

Background Pirfenidone has demonstrated significant anti‐inflammatory and antifibrotic
effects in both animal models and some clinical trials. Its potential for antifibrotic activity …

Gynaecological health is a neglected field of research that includes conditions such as
endometriosis, uterine fibroids, infertility, viral and bacterial infections, and cancers. There is …

Abstract Background Therapeutic microRNAs (miRNAs) delivery holds a lot of promise for
treating human malignancies. So, this study was carried out to examine the potential of miR …

The increasing prevalence of non-alcoholic fatty liver disease (NAFLD), as well as its
advanced stage non-alcoholic steatohepatitis (NASH) with the progression of liver …